Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426320 | 1.00 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL419252 | 0.92 | — | — | |
| SCHEMBL419251 | 0.92 | — | — | |
| SCHEMBL424063 | 0.85 | CHRNB2 (0.31) | — | |
| SCHEMBL424064 | 0.85 | CHRNB2 (0.31) | — | |
| SCHEMBL424753 | 0.77 | — | — | |
| SCHEMBL424752 | 0.77 | — | — | |
| SCHEMBL10060050 | 0.77 | — | — | |
| SCHEMBL425614 | 0.77 | — | — | |
| SCHEMBL425613 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022053-A1 | Oxadiazine Derivatives | SYNGENTA CROP PROTECTION, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7655650-B2 | Oxadiazine derivatives | Syngenta Corporation (US) | 2010-02-02 | — | — | US | disclosed |
| US-20030232821-A1 | Oxadiazine derivatives | MAIENFISCH PETER (CH) | 2003-12-18 | — | — | US | disclosed |
| US-6627753-B1 | Agricultural insecticides | SYNGENTA INVESTMENT CORPORATION | 2003-09-30 | — | — | US | disclosed |
| US-6376487-B1 | SELECTIVE INSECTICIDES FOR KILLING FLIES, ROACHES, WEEVILS, AND OTHER PESTS; FOR USE ON COTTON, LEGUMES, FRUITS, CEREALS, BEANS, AND OTHER CROPS | SYNGENTA INVESTMENT CORP. | 2002-04-23 | — | — | US | disclosed |
| US-6022871-A | INSECTICIDES | NOVARTIS CORPORATION (US) | 2000-02-08 | — | — | US | disclosed |
| US-5852012-A | Oxadiazine derivatives | NOVARTIS CORPORATION (US) | 1998-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232821-A1 | Oxadiazine derivatives | HCN1, SCO2, AOC3 | MEN1 3619/4885KMT2A 3441/4885 |
| US-20120022053-A1 | Oxadiazine Derivatives | CBR3, AOC3, AOC2 | MEN1 4077/4885KMT2A 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.